Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: LENSAR Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
LENSAR Inc. August 4, 202687.6%
-
Ocular Therapeutix Inc. June 11, 202580.7%
-
LENSAR Inc. May 25, 202384.4%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 10, 2026 | Ocular Therapeutix Inc. | Grant or award | +14,000 | — | — |
| Jun 3, 2026 | LENSAR Inc. | Grant or award | +17,421 | — | — |
| Feb 20, 2026 | Ocular Therapeutix Inc. | Open-market purchase | +60,229 | $7.66 | $461,354 |
| Jun 11, 2025 | Ocular Therapeutix Inc. | Grant or award | +14,000 | — | — |
| May 23, 2025 | LENSAR Inc. | Grant or award | +7,374 | — | — |
| May 8, 2025 | Ocular Therapeutix Inc. | Open-market purchase | +10,000 | $6.96 | $69,600 |
| Jul 24, 2024 | Ocular Therapeutix Inc. | Grant or award | +12,000 | — | — |
| May 7, 2024 | LENSAR Inc. | Grant or award | +22,000 | — | — |
| Feb 27, 2024 | Ocular Therapeutix Inc. | Option exercise | +18,939 | $8.80 | $166,663 |
| Feb 27, 2024 | Ocular Therapeutix Inc. | Option exercise | +11,363 | $8.80 | $99,994 |
| Jun 14, 2023 | Ocular Therapeutix Inc. | Grant or award | +12,000 | — | — |
| May 25, 2023 | LENSAR Inc. | Grant or award | +9,288 | — | — |
Questions about Richard L. Lindstrom M.D.
What boards is Richard L. Lindstrom M.D. on?
Richard L. Lindstrom M.D. sits on the boards of LENSAR Inc. and Ocular Therapeutix Inc.
How long has Richard L. Lindstrom M.D. served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.